Skip to content

VALN

Valneva SE

NASDAQ · Healthcare · Biotechnology · FR

$5.51
−1.78%
Ask drillr

Year over year

Reported trailing growth

Revenue
-26.9%
EBITDA
—
EBIT
—
EPS
-97.8%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
+22.3%
EBITDA
+75.1%
EPS
+48.5%

Three-year CAGR

Revenue
-21.5%
EBITDA
—
EBIT
—
Net income
—
EPS
—
Free cash flow
+31.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026